Erik J. van Helden

Radiomics analysis of pre-treatment [18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment

Erik J. van Helden, Younan J.L. Vacher, Wessel N. van Wieringen et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 65 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

<i><scp>RAS</scp></i> and <i><scp>BRAF</scp></i> mutations in cell‐free <scp>DNA</scp> are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested <i><scp>RAS</scp></i> wild‐type advanced colorectal cancer

Erik J. van Helden, Lindsay Angus, C. Willemien Menke‐van der Houven van Oordt et al. · Molecular Oncology · 2019 · 54 citations · Full text

Medicine, Oncology, Cancer Genetics +16

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

Erik J. van Helden, Sjoerd G. Elias, Sophie L. Gerritse et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17

Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results

Suzanne C. van Es, Bert van der Vegt, Frederike Bensch et al. · The American Journal of Surgical Pathology · 2019 · 31 citations · Full text

Medicine, Oncology, Breast Oncology +15